Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG EBITDA Margin
EBITDA as a percentage of revenue.
Pulmonx CorporationNASDAQ: LUNG
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -59.8%
EBITDA Margin was -59.8% in Q1 FY2026, up 4.8 pp from a year earlier. On a trailing-twelve-month basis it was -54.5%, up 6.4 pp year over year. Over 3 fiscal years it widened by 50.0 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -37.7% for the fiscal year ending Dec 2026, up from -54.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -59.8%-18.9 pp QoQ
- Last fiscal yearDec 2025
- -54.3%+6.3 pp YoY
- LTMMar 2026
- -54.5%+6.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.8 pp | +10.7 pp | +5.9 pp |
| 1 year | +6.3 pp | +16.6 pp | +10.3 pp |
| 3 years | +50.0 pp | +31.9 pp | -18.1 pp |
| 5 years | +47.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -54.3%
- Year-over-year change
- +6.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -54.3% | +6.3pp |
| FY2024 | 2024-12-31 | -60.6% | +19.6pp |
| FY2023 | 2023-12-31 | -80.2% | +24.1pp |
| FY2022 | 2022-12-31 | -104.3% | -8.0pp |
| FY2021 | 2021-12-31 | -96.3% | — |
EBITDA Margin vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 EBITDA Margin of -54.5% is the 4th highest of the 6 companies compared; the peer median is -41.4%.
- Its year-over-year change of +6.4 pp is the 4th highest of 6, against a peer median of +115.0 pp.
- Over three fiscal years its change of +50.0 pp compares with a peer median of +54.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 18.5% | +115.0 pp | +94012.8 pp | |
| LTM Mar 2026 | -5.7% | -8.3 pp | -55.1 pp | |
| LTM Jun 2026 | -41.4% | +4.7 pp | +54.0 pp | |
| LTM Mar 2026 | -54.5% | +6.4 pp | +50.0 pp | |
| LTM Mar 2026 | -216.2% | +118.9 pp | +812.8 pp | |
| LTM Mar 2026 | -1298.7% | +1519.2 pp | -759.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding LUNG) | -41.4% | +115.0 pp | +54.0 pp | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.42M | 53.66M | 68.68M | 83.79M | 90.5M |
| Cost of Revenue | 12.79M | 13.8M | 17.92M | 21.79M | 23.36M |
| Gross Profit | 35.63M | 39.87M | 50.75M | 62M | 67.14M |
| Gross Margin | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Research & Development | 13.06M | 15.4M | 18.08M | 17.57M | 19.49M |
| Selling, General & Admin | 69.87M | 83.11M | 94.61M | 102.14M | 101.31M |
| Operating Expenses | 82.93M | 98.5M | 112.69M | 119.71M | 120.8M |
| Depreciation & Amortization | 867K | 1.51M | 1.95M | 1.59M | 1.05M |
| EBITDA | (46.62M) | (55.99M) | (55.09M) | (50.79M) | (49.17M) |
| EBITDA Margin | -96.3% | -104.3% | -80.2% | -60.6% | -54.3% |
| Operating Income | (47.3M) | (58.64M) | (61.94M) | (57.7M) | (53.66M) |
| Operating Margin | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Interest Income | 400K | 1.53M | 5.57M | 5.06M | 2.65M |
| Interest Expense | 829K | 1.07M | 3.23M | 3.51M | 3.16M |
| Other Income / Expenses | (1.01M) | 67K | 1.66M | 1.81M | 286K |
| Income Before Tax | (48.32M) | (58.57M) | (60.27M) | (55.89M) | (53.38M) |
| Pre-Tax Margin | -99.8% | -109.1% | -87.8% | -66.7% | -59.0% |
| Income Tax Expense | 343K | 353K | 571K | 500K | 626K |
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Net Margin | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| EPS (Basic) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| EPS (Diluted) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| Weighted Avg Shares | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
| Weighted Avg Shares (Diluted) | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.